HAPPE Spine, founded in 2018, positions itself as a transformative force in the realm of orthopedic and spinal implants through its innovative HAPPE™ (HydroxyApatite Porous PEEK) platform. Specializing in the intersection of Health Care, Information Technology, and Manufacturing, the company aims to revolutionize implant technology by enhancing bone integration.
With headquarters in the United States, HAPPE Spine's material platform incorporates interconnected, cancellous porosity along with exposed hydroxyapatite surfaces, which substantially aids bone in-growth and on-growth. The efficacy of this technology has been confirmed through rigorous preclinical testing.
The company secured a significant $5.33 million Series A investment on 26 August 2021, led by Cultivate(MD). This infusion of capital underscores investor confidence in HAPPE Spine's potential to innovate within the medical device industry, offering promising opportunities for stakeholders attentive to advances in implant technologies.